A detailed history of M&T Bank Corp transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, M&T Bank Corp holds 6,467 shares of RARE stock, worth $359,241. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,467
Previous 6,535 1.04%
Holding current value
$359,241
Previous $305,000 13.11%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$37.42 - $51.61 $2,544 - $3,509
-68 Reduced 1.04%
6,467 $265,000
Q1 2024

May 07, 2024

BUY
$43.02 - $53.69 $2,107 - $2,630
49 Added 0.76%
6,535 $305,000
Q4 2023

Feb 06, 2024

BUY
$31.73 - $49.19 $205,800 - $319,046
6,486 New
6,486 $310,000
Q2 2023

Aug 09, 2023

BUY
$37.35 - $52.15 $167,103 - $233,319
4,474 New
4,474 $206,000
Q4 2022

Feb 13, 2023

BUY
$33.72 - $46.33 $269 - $370
8 Added 0.18%
4,497 $208,000
Q4 2022

Feb 13, 2023

BUY
$33.72 - $46.33 $151,369 - $207,975
4,489 New
4,489 $207,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.89B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.